Structural snapshots illustrate the catalytic cycle of β- galactocerebrosidase, the defective enzyme in Krabbe disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 51, 2013, Pages 20479-20484

  Hill, Chris H ^a   Graham, Stephen C ^b   Read, Randy J ^a   Deane, Janet E ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

galactosylceramidase; Glycosyl hydrolase; Lysosomal storage disease; Pharmacological chaperone therapy

Indexed keywords

GALACTOSYLCERAMIDASE; GLYCOSIDASE;

ARTICLE; CATALYSIS; CONFORMATIONAL TRANSITION; COVALENT BOND; CRYSTAL STRUCTURE; DEMYELINATION; ENZYME KINETICS; GLOBOID CELL LEUKODYSTROPHY; KINETICS; LYSOSOME STORAGE DISEASE; MAMMAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

EID: 84890835192     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1311990110     Document Type: Article

References (54)

1. Nagano S, et al. (1998) Expression and processing of recombinant human galactosylceramidase. Clin Chim Acta 276(1):53-61.
2. Beier UH, Görögh T (2005) Implications of galactocerebrosidase and galactosylcerebroside metabolism in cancer cells. Int J Cancer 115(1):6-10.
3. Liu Y, et al. (2011) GALC deletions increase the risk of primary open-Angle glaucoma: The role of Mendelian variants in complex disease. PLoS ONE 6(11):e27134.
4. Visigalli I, et al. (2010) The galactocerebrosidase enzyme contributes to the maintenance of a functional hematopoietic stem cell niche. Blood 116(11):1857-1866.
5. Sandhoff K, Kolter T (1996) Topology of glycosphingolipid degradation. Trends Cell Biol 6(3):98-103.
6. Davies G, Henrissat B (1995) Structures and mechanisms of glycosyl hydrolases. Structure 3(9):853-859.
7. Deane JE, et al. (2011) Insights into Krabbe disease from structures of galactocerebrosidase. Proc Natl Acad Sci USA 108(37):15169-15173.
8. Kanazawa T, et al. (2000) Inhibition of cytokinesis by a lipid metabolite, psychosine. J Cell Biol 149(4):943-950.
9. Giri S, Khan M, Rattan R, Singh I, Singh AK (2006) Krabbe disease: Psychosine-Mediated activation of phospholipase A2 in oligodendrocyte cell death. J Lipid Res 47(7):1478-1492.
10. Formichi P, et al. (2007) Psychosine-Induced apoptosis and cytokine activation in immune peripheral cells of Krabbe patients. J Cell Physiol 212(3):737-743.
11. D'Agostino AN, Sayre GP, Hayles AB (1963) Krabbe's disease. Globoid cell type of leukodystrophy. Arch Neurol 8:82-96.
12. Tanaka K, Nagara H, Kobayashi T, Goto I (1988) The twitcher mouse: Accumulation of galactosylsphingosine and pathology of the sciatic nerve. Brain Res 454(1-2):340-346.
13. Rafi MA, Luzi P, Zlotogora J, Wenger DA (1996) Two different mutations are responsible for Krabbe disease in the Druze and Moslem Arab populations in Israel. Hum Genet 97(3):304-308.
14. Tappino B, et al. (2010) Identification and characterization of 15 novel GALC gene mutations causing Krabbe disease. Hum Mutat 31(12):E1894-E1914.
15. Fiumara A, et al. (2011) Krabbe leukodystrophy in a selected population with high rate of late onset forms: Longer survival linked to c.121G>A (p.Gly41Ser) mutation. Clin Genet 80(5):452-458.
16. De Gasperi R, et al. (1996) Molecular heterogeneity of late-Onset forms of globoid-Cell leukodystrophy. Am J Hum Genet 59(6):1233-1242.
17. Wenger DA, Rafi MA, Luzi P (1997) Molecular genetics of Krabbe disease (globoid cell leukodystrophy): Diagnostic and clinical implications. Hum Mutat 10(4):268-279.
18. Xu C, Sakai N, Taniike M, Inui K, Ozono K (2006) Six novel mutations detected in the GALC gene in 17 Japanese patients with Krabbe disease, and new genotype-Phenotype correlation. J Hum Genet 51(6):548-554.
19. Lissens W, et al. (2007) A single mutation in the GALC gene is responsible for the majority of late onset Krabbe disease patients in the Catania (Sicily, Italy) region. Hum Mutat 28(7):742.
20. Fu L, et al. (1999) Molecular heterogeneity of Krabbe disease. J Inherit Metab Dis 22(2):155-162.
21. Furuya H, et al. (1997) Adult onset globoid cell leukodystrophy (Krabbe disease): Analysis of galactosylceramidase cDNA from four Japanese patients. Hum Genet 100(3-4):450-456.
22. Cohen FE, Kelly JW (2003) Therapeutic approaches to protein-Misfolding diseases. Nature 426(6968):905-909.
23. Parenti G (2009) Treating lysosomal storage diseases with pharmacological chaperones: From concept to clinics. EMBO Mol Med 1(5):268-279.
24. Fan JQ (2003) A contradictory treatment for lysosomal storage disorders: Inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 24(7):355-360.
25. Lieberman RL, et al. (2007) Structure of acid beta-Glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol 3(2):101-107.
26. Brumshtein B, et al. (2007) Crystal structures of complexes of N-Butyl-And N-Nonyldeoxynojirimycin bound to acid beta-Glucosidase: Insights into the mechanism of chemical chaperone action in Gaucher disease. J Biol Chem 282(39):29052-29058.
27. Sun Y, et al. (2012) Ex vivo and in vivo effects of isofagomine on acid â-Glucosidase variants and substrate levels in Gaucher disease. J Biol Chem 287(6):4275-4287.
28. Guce AI, Clark NE, Rogich JJ, Garman SC (2011) The molecular basis of pharmacological chaperoning in human á-Galactosidase. Chem Biol 18(12):1521-1526.
29. Asano N, et al. (2000) In vitro inhibition and intracellular enhancement of lysosomal alpha-Galactosidase A activity in Fabry lymphoblasts by 1-Deoxygalactonojirimycin and its derivatives. Eur J Biochem 267(13):4179-4186.
30. Chen YQ, Wenger DA (1993) Galactocerebrosidase from human urine: Purification and partial characterization. Biochim Biophys Acta 1170(1):53-61.
31. Sakai N, et al. (1994) Purification and characterization of galactocerebrosidase from human lymphocytes. J Biochem 116(3):615-620.
32. Guce AI, et al. (2010) Catalytic mechanism of human alpha-Galactosidase. J Biol Chem 285(6):3625-3632.
33. Juers DH, et al. (2001) A structural view of the action of Escherichia coli (lacZ) betagalactosidase. Biochemistry 40(49):14781-14794.
34. Huber RE, Wallenfels K, Kurz G (1975) The action of beta-Galactosidase (Escherichia coli) on allolactose. Can J Biochem 53(9):1035-1038.
35. Hajdu J, et al. (2000) Analyzing protein functions in four dimensions. Nat Struct Biol 7(11):1006-1012.
36. Hajdu J (1993) Fast crystallography and time-Resolved structures. Annu Rev Biophys Biomol Struct 22:467-498.
37. Wei RR, et al. (2011) X-Ray and biochemical analysis of N370S mutant human acid â-Glucosidase. J Biol Chem 286(1):299-308.
38. Sandhoff K, Kolter T (2003) Biosynthesis and degradation of mammalian glycosphingolipids. Philos Trans R Soc Lond B Biol Sci 358(1433):847-861.
39. Harzer K, et al. (1997) Saposins (sap) A and C activate the degradation of galactosylceramide in living cells. FEBS Lett 417(3):270-274.
40. Vocadlo DJ, Davies GJ (2008) Mechanistic insights into glycosidase chemistry. Curr Opin Chem Biol 12(5):539-555.
41. Wentworth DF, Wolfenden R (1974) Slow binding of D-Galactal, a reversible inhibitor of bacterial beta-Galactosidase. Biochemistry 13(23):4715-4720.
42. Vocadlo DJ, Davies GJ, Laine R, Withers SG (2001) Catalysis by hen egg-White lysozyme proceeds via a covalent intermediate. Nature 412(6849):835-838.
43. Millard CB, et al. (1999) Reaction products of acetylcholinesterase and VX reveal a mobile histidine in the catalytic triad. J Am Chem Soc 121(42):9883-9884.
44. Barabas O, et al. (2013) Catalytic mechanism of alpha-Phosphate attack in dUTPase is revealed by X-Ray crystallographic snapshots of distinct intermediates, 31P-NMR spectroscopy and reaction path modelling. Nucleic Acids Res, 10.1093/nar/gkt756.
45. Selleri S, et al. (2000) Deletion of exons 11-17 and novel mutations of the galactocerebrosidase gene in adult-And early-Onset patients with Krabbe disease. J Neurol 247(11):875-877.
46. Sulzenbacher G, Driguez H, Henrissat B, Schülein M, Davies GJ (1996) Structure of the Fusarium oxysporum endoglucanase I with a nonhydrolyzable substrate analogue: Substrate distortion gives rise to the preferred axial orientation for the leaving group. Biochemistry 35(48):15280-15287.
47. Tews I, et al. (1996) Bacterial chitobiase structure provides insight into catalytic mechanism and the basis of Tay-Sachs disease. Nat Struct Biol 3(7):638-648.
48. Schueler UH, et al. (2004) Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J Inherit Metab Dis 27(5):649-658.
49. Ribbens J, et al. (2013) A high-Throughput screening assay using Krabbe disease patient cells. Anal Biochem 434(1):15-25.
50. Lee WC, et al. (2010) Molecular characterization of mutations that cause globoid cell leukodystrophy and pharmacological rescue using small molecule chemical chaperones. J Neurosci 30(16):5489-5497.
51. Yuzwa SA, et al. (2008) A potent mechanism-Inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol 4(8):483-490.
52. Ficko-Blean E, Stubbs KA, Nemirovsky O, Vocadlo DJ, Boraston AB (2008) Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB. Proc Natl Acad Sci USA 105(18):6560-6565.
53. Sánchez-Ollé G, et al. (2009) Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease. Blood Cells Mol Dis 42(2):159-166.
54. Walter TS, et al. (2008) Semi-Automated microseeding of nanolitre crystallization experiments. Acta Crystallogr Sect F Struct Biol Cryst Commun 64(Pt 1):14-18.